Company Overview
Cellceutix Corporation is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Our primary efforts are in cancer and inflammatory disease. We intend to spend most of our time initially on our lead product, Kevetrin, which is being developed for drug-resistant cancers. We've recently announced some exciting results in animal models of multi-drug resistant lung cancer.
-
Click links to view summary of data.
We'll focus on developing the highest quality data and intellectual property to support Kevetrin so we can move it as quickly as possible along the regulatory pathway. We have five other exciting compounds in our pipeline that we will progress as resources become available.
Business Strategy:
Our business strategy is simple. We want to make the most of what we have and use it to benefit patients. Benefits for patients will translate into benefits for investors.
We think "Compounds for Cures" sums it up pretty well. We have an exciting pipeline of products with the potential to help patients and an experienced management team that can move these products forward. We'll start with Kevetrin. We have several studies we need to do before we can ask FDA for permission to begin studies in humans. We want to do these as quickly as possible. And we won't get distracted. We believe many companies fail due to their inability to stay focused on the critical items that provide value for patients and shareholders. At Cellceutix we have the ability and the commitment to stay focused on those critical items.
Cellceutix is a publicly traded company trading under the stock symbol CTIX.OB on the bulletin board listings. Cellceutix is located outside of Boston, Massachusetts. The company's initial focus is the development and commercialization of its leading cancer compound, Kevetrin, as well as other compounds for cancer and inflammatory disease. The senior management of Cellceutix is composed of people with long experience in researching, developing and marketing innovative pharmaceutical products.
Cellceutix was formed in May of 2007 by George Evans and Dr. Krishna Menon. The organization will develop the innovations of Dr. Menon and his team in the laboratory. The company owns intellectual property stemming from the inventions of Dr. Krishna Menon, whose background consists of over 35 years of experience working as team leader in drug development for top pharmaceutical companies and academic institutions. The Company also owns intellectual property developed by several prominent scientists and researchers.
Cellceutix is open to new partnerships that compliment its business strategy, technology and mission. In a growing industry with quickly advancing technologies for such things as drug delivery, biomarkers, etc., partnerships can advance the development process and at the same time provide business opportunities for a variety of partners. If your company is interested in finding out more about partnership opportunities please contact us at
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it and someone in our business development department will get back to you promptly.
Through internal research and development as well as external alliances, Cellceutix has assembled an exciting pipeline of unique compounds which have shown promise in cancer and inflammatory disease. Spanning indications from cancer to neural disorders, the drug candidates in development have been chosen for their innovative characteristics and potential to improve patient care.
| 
Home 
Sitemap
Contact Us
Kevetrin